{
    "clinical_study": {
        "@rank": "48558", 
        "arm_group": [
            {
                "arm_group_label": "Methotrexate", 
                "arm_group_type": "Active Comparator", 
                "description": "Single agent Methotrexate 15 to 25 mg PO per week"
            }, 
            {
                "arm_group_label": "Combination", 
                "arm_group_type": "Active Comparator", 
                "description": "Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day"
            }, 
            {
                "arm_group_label": "Combination Steroid", 
                "arm_group_type": "Experimental", 
                "description": "Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Many studies have been conducted to evaluate the role of pulse steroids in early rheumatoid\n      arthritis (RA) but no consensus exists. The aim of this study is to study the efficacy of\n      various treatment regimens in early RA. Methods:  This is a randomized open-labeled trial.\n      Patients were randomised into three groups. In group A, patients were treated with single\n      drug (methotrexate 15 mg/wk). The patients in Group B were treated with a combination of\n      DMARDS (Methotrexate, sulfasalazine and hydroxychloroquine). The patients in Group C\n      received combination therapy as in group B and 3 pulses of methylprednisolone intravenously."
        }, 
        "brief_title": "Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Many studies have been conducted to evaluate the role of pulse steroids in early rheumatoid\n      arthritis (RA) but no consensus exists. The aim of this study is to study the efficacy of\n      various treatment regimens in early RA. Patients were divided into three groups. In group A,\n      patients were treated with single drug (methotrexate 15 mg/wk). The patients in Group B were\n      treated with a combination of DMARDS (Methotrexate, sulfasalazine and hydroxychloroquine).\n      The patients in Group C received combination therapy as in group B and 3 pulses of\n      methylprednisolone intravenously."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Rheumatoid Arthritis diagnosed on the basis of revised American college of\n             rheumatology criteria,1987\n\n          2. Age >18 years\n\n          3. Early Rheumatoid Arthritis i.e. less than 2 years duration\n\n          4. Patient giving consent to participate in study\n\n          5. Disease Modifying Anti-Rheumatic Drugs naive -\n\n        Exclusion Criteria:\n\n          1. Pregnant and lactating patient or planning to conceive in next year\n\n          2. Patient who had joint surgery in last 6 months\n\n          3. Co morbidities such as liver disease, kidney disease, hematological malignancies\n\n          4. Uncontrolled hypertension, diabetes mellitus\n\n          5. Coronary artery disease -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870128", 
            "org_study_id": "T-54/ 12.06.2009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combination Steroid", 
                "description": "Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day", 
                "intervention_name": "Combination Steroid", 
                "intervention_type": "Drug", 
                "other_name": "Methylprednisolone 1000 mg intravenous for 3 days"
            }, 
            {
                "arm_group_label": "Methotrexate", 
                "description": "Methotrexate 15 to 25 mg PO per week", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug", 
                "other_name": "Methotrexate 15 to 25 mg PO per week"
            }, 
            {
                "arm_group_label": "Combination", 
                "description": "Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day", 
                "intervention_name": "Combination", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Methotrexate 15 to 25 mg PO per week", 
                    "Hydroxychloroquine 200 mg Twice daily", 
                    "Sulfasalazine 2000 to 3000 mg per day"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydroxychloroquine", 
                "Methotrexate", 
                "Sulfasalazine", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rheumatoid arthritis", 
            "Steroid"
        ], 
        "lastchanged_date": "June 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110029"
                }, 
                "name": "AIIMS"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial", 
        "overall_official": {
            "affiliation": "All India Institute of Medical Sciences, New Delhi", 
            "last_name": "ATUL BATRA, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Indian Council of Medical Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To compare the  response (EULAR criteria)  to treatment  in the three treatment groups.", 
            "measure": "Response to treatment", 
            "safety_issue": "No", 
            "time_frame": "22 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870128"
        }, 
        "responsible_party": {
            "investigator_affiliation": "All India Institute of Medical Sciences, New Delhi", 
            "investigator_full_name": "Atul Batra", 
            "investigator_title": "Senio Resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To compare the disease activity  score  (DAS28) score and its defining variables (tender joint count, swollen joint count, erythrocyte sedimentation rate and patient global assessment on visual analogue scale).", 
            "measure": "Disease activity  score  (DAS28)", 
            "safety_issue": "No", 
            "time_frame": "22 months"
        }, 
        "source": "All India Institute of Medical Sciences, New Delhi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "All India Institute of Medical Sciences, New Delhi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}